Aurobindo Pharma Ltd. - Quarterly/Annual Result Disclosures and Notes dated 31 Dec 2021

1. The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.



2. The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 09 February 2022. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2021. An unmodified report has been issued by them thereon.



3. The Company operates in only one segment viz., 'Pharmaceutical Products'.



4. Sales of standalone include exports of Rs.166,064 lakhs for the current quarter (31 December 2020: Rs.328,492 lakhs).



5. As at 31 December 2021, the Company has not elected to apply tax rate prescribed under Section 115BAA of the Income tax Act, 1961 and accordingly continue to account for income taxes under old tax rate.



6. During the financial year 2019-20, the Board of directors of the Company has approved for amalgamation of the five subsidiary Companies with Aurobindo Pharma Limited, the holding company with the appointed date of 1 April 2019. Accordingly, a Scheme of Amalgamation for merger of APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited (a stepdown wholly owned subsidiary) with the Company was filed before the Hon’ble National Company Law Tribunal, Hyderabad (NCLT). Further, during the previous year, a modified Scheme Amalgamation was filed with the Hon’ble NCLT by way of filing an Interlocutory application for removal and complete exclusion of the APL Healthcare Limited as a party to the Scheme of Amalgamation. The Hon’ble NCLT vide order dated 30 March 2021 has approved the modified scheme of amalgamation and a certified copy has been filed by the Company with the Registrar of Companies, Telangana 29 April 2021. Accordingly, the subsidiaries viz. APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited (a stepdown wholly owned subsidiary) have now been merged with Aurobindo Pharma Limited. The appointed date as per the NCLT approved Scheme is 1 April 2019, which is the same as the beginning of the preceding period in the financial statements and hence, in line with the Scheme, the combination has been accounted for from that date as per the requirements of Appendix C to Ind AS 103 “Business Combination”. Accordingly, the amounts relating to three months and nine months ended 31 December 2020 shown in the statement include the impact of the business combination and have been restated after recognising the effect of the Scheme as above.



Particulars Quarter ended 31.12.2020 Nine months ended

31.12.2020



Total income 1,766 3,802

Total expenses 2,386 6,010

Loss before tax (620) (2,208)

Tax expense/(benefit) (160) (568)

Profit/(Loss) after tax (460) (1,640)



7. The Company continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Company continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. The Company has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity in other markets. Based on internal and external sources of information, current economic environment and future economic indicators, the Company has assessed the financial impact of the COVID-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. Wherever considered necessary an assessment of the impact has been carried out and the necessary adjustments if material have been recorded. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Company will continue to monitor any material changes to future economic conditions.



8. During the nine months period the following units were transferred within the Group:



The Board of Aurobindo Pharma Limited on 27 February 2021 had approved the transfer of its oral formulations business comprised in Unit 10 located at Multiproduct Special Economic Zone, Naidupet, Mandal, SPSR Nellore District, Andhra Pradesh to its wholly-owned subsidairy APL Healthcare Limited through a slump sale. Undertaking was transferred for consideration of Rs.131,500 lakhs.



The Board of Aurobindo Pharma Limited in their meeting held on 1st July 2021 approved the transfer of business undertaking comprised in Unit-4 of the Company located at Pashamylaram, Pattancheru Mandal, Sangareddy district, Telangana, to Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company. Undertaking was transfered for consideration of Rs.93,850 lakhs.



The Board of Aurobindo Pharma Limited in their meeting held on 31st May 2021 approved Transfer of business undertaking comprised in Unit-16 of the Company located at TSIIC, SEZ, Polepally Village, Jadcherla Mandal, Mahbubnagar district, Telangana, to Wytells Pharma Private Limited, a wholly owned step-down subsidiary of the Company and 100% subsidiary of Eugia Pharma Specialities Limited. Undertaking was transfered for consideration of Rs.29,415 lakhs.



Due to the above transfers the Company has recorded a capital gain tax of Rs.2563 lakhs and a reversal of deferred tax amounting to Rs.8361 lakhs.



9. The Board of Directors of the Company as part of Company’s Verticalization of Vaccines Business, in its meeting held on 31 December 2021 approved the sale and transfer of injectables undertaking of Unit 18 of the Company located at Survey No.69, 70, 71 & 72, Indrakaran Village, Kandi Mandal, Sangareddy District - 502203, Telangana, to Auro Vaccines Private Limited, a wholly owned subsidiary of the Company. This transfer is aimed at segregation of the vaccines business and subsidiarization of vaccines business in an special purpose vehicle. The slump sale of Unit 18 shall be made effective from January 1, 2022 for a lumpsum consideration of INR 299 crores (Rupees Two Hundred and Ninety-Nine Crores) based on the value of assets and liabilities as on 30 September 2021. The final consideration for transfer of Unit 18 will be adjusted based on the change in values of assets and liabilities between 1 October 2021 and 31 December 2021 (on a cash free basis). Unit 18 is yet to commence commercial operations.



10. The Board has approved interim dividend @150% i.e.Re.1.50 (Rupee one and paisa fifty only) per equity share of Re.1/- (Rupee one only) for the year 2021-22.